Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Nov 12;3(21):3196-3200.
doi: 10.1182/bloodadvances.2019000646.

Second primary malignancies in ruxolitinib-treated myelofibrosis: real-world evidence from 219 consecutive patients

Margherita Maffioli  1 , Toni Giorgino  2   3 , Barbara Mora  1 , Alessandra Iurlo  4 , Elena Elli  5 , Maria Chiara Finazzi  6 , Marianna Caramella  7 , Elisa Rumi  8 , Maria Cristina Carraro  9 , Nicola Polverelli  10 , Mariella D'Adda  11 , Simona Malato  12 , Marianna Rossi  13 , Alfredo Molteni  14 , Alessandro Vismara  15 , Cinzia Sissa  16 , Francesco Spina  17 , Michela Anghilieri  18 , Daniele Cattaneo  4 , Rossella Renso  5 , Marta Bellini  6 , Maria Luisa Pioltelli  7 , Chiara Cavalloni  8 , Daniela Barraco  1 , Raffaella Accetta  19 , Lorenza Bertù  20 , Matteo Giovanni Della Porta  13 , Francesco Passamonti  20
Affiliations

Second primary malignancies in ruxolitinib-treated myelofibrosis: real-world evidence from 219 consecutive patients

Margherita Maffioli et al. Blood Adv. .

Abstract

  1. We present real-world data on all ruxolitinib-treated myelofibrosis patients in a 10-million-resident region, with a follow-up of 2 years.

  2. We found no evidence of an increased risk of developing lymphomas.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: A.I. received speaker honoraria from Novartis, Pfizer, and Incyte. E.R. received consultancy fees from Novartis. F.P. received speaker honoraria from Novartis and Celgene, and participated in advisory boards for Celgene, Novartis, Roche, Janssen, Incyte, and AbbVie. The remaining authors declare no competing financial interests.

Figures

Figure 1.
Figure 1.
Cumulative incidence of SPMs (excluding NMSCs) after RUX start.
See this image and copyright information in PMC

References

    1. Rumi E, Passamonti F, Elena C, et al. . Increased risk of lymphoid neoplasm in patients with myeloproliferative neoplasm: a study of 1,915 patients. Haematologica. 2011;96(3):454-458. - PMC - PubMed
    1. Frederiksen H, Farkas DK, Christiansen CF, Hasselbalch HC, Sørensen HT. Chronic myeloproliferative neoplasms and subsequent cancer risk: a Danish population-based cohort study. Blood. 2011;118(25):6515-6520. - PubMed
    1. Susini MC, Masala G, Antonioli E, et al. . Risk of second cancers in chronic myeloproliferative neoplasms. Blood. 2012;119(16):3861-3862; author reply 3862-3863. - PubMed
    1. Barbui T, Ghirardi A, Masciulli A, et al. . Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study. Leukemia. 2019;33(8):1996-2005. - PubMed
    1. Brunner AM, Hobbs G, Jalbut MM, Neuberg DS, Fathi AT. A population-based analysis of second malignancies among patients with myeloproliferative neoplasms in the SEER database. Leuk Lymphoma. 2016;57(5):1197-1200. - PMC - PubMed

Publication types

MeSH terms